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Evolution of class switching
 
Antibody class switching emerged in evolutionary history when bony fish grew 
legs and became amphibians. On page 733, Barreto and colleagues show that 
the switch-inducing enzyme AID (activation-induced cytidine deaminase) is in 
working order in bony fish, suggesting that the evolution of the switch 
reaction had to wait for the acquisition of some other component.
Bony fish produce antibodies but lack class switch recombination, a process 
by which the constant region of the antibody heavy chain is swapped for that of 
a different isotype. This process is missing in fish despite the expression of AID and 
the presence of antibody somatic hypermutation, a process also initiated by AID.
This group recently showed that COOH-terminal mutations in AID robbed the 
enzyme of its class-switching function without affecting hypermutation. The 
zebrafish AID gene contains COOH-terminal mutations, suggesting that fish AID 
might be unable to recruit essential cofactors or to bind appropriately to the heavy 
chain locus. But Barreto et al. now show that AID from zebrafish restored normal 
class switching in AID-deficient mouse B cells, indicating that the functional 
domains of AID that are required for class switching were all intact. 
Thus it appears that the rate-limiting step for class switching was not the 
evolution of a switch-capable AID protein, but rather the evolution of appropriate 
DNA switch regions, which are indeed missing from fish heavy chain locus. 
 
Blocking acid, boosting T cells
 
Intracellular antacids boost cytotoxic T cell responses, according to a study on
page 817. Accapezzato and colleagues show that an inhibitor that prevents
endosome acidification enhances presentation of antigens to CD8
 
 
 
 T cells
and boosts vaccine responses.
Many vaccines are made of soluble proteins derived from viruses or
bacteria. But these vaccines tend to be poor stimulators of CD8
 
 
 
 T cells, as
soluble antigens are primarily degraded in acidified endosomes; the resulting
peptides are loaded onto MHC class II molecules and presented to CD4
 
 
 
helper T cells. But in certain cell types, exogenous antigen can escape from
endosomes and enter the cytosol. From there, the antigen can infiltrate the
class I MHC processing pathway—which is normally reserved for internally
synthesized proteins—and be cross-presented to CD8
 
 
 
 T cells.
Accapezzato and colleagues now show that cross-presentation is
enhanced when antigen-pulsed dendritic cells are treated with chloroquine,
a widely used antimalarial drug that prevents endosome acidification. The
enhancement was due to both decreased antigen degradation and increased
escape of antigen into the cytosol. The latter finding is consistent with a
recent study showing that chloroquine can increase membrane permeability.
A single dose of oral chloroquine given to recipients of hepatitis B
virus booster shots resulted in detectable CD8
 
 
 
 T cell responses in
nearly 70% of the recipi-
ents, compared with no
responses in those who
received the shot alone.
This readily available
drug might thus be a use-
ful T cell–boosting sup-
plement to soluble antigen
vaccines. 
Chloroquine gets soluble antigens out of endosomes 
(right) and into the cytoplasm (left).
 
Modifying Aire
 
Genetic background can dictate the target and 
severity of an autoimmune attack that results 
from a single genetic mutation, according to Jiang 
and colleagues on page 805.
Most autoimmune diseases are caused by 
multiple genetic defects that conspire to break 
down the immune system’s tolerance to self-
tissues. One exception is autoimmunity caused 
by mutations in Aire, the transcriptional 
regulator that controls tolerance by driving the 
expression of tissue-restricted genes in thymic 
epithelial cells. Thymic expression of these 
genes causes self-reactive T cells to be either 
deleted or tolerized. Mice and humans with 
mutations in Aire develop autoimmune 
symptoms that vary widely in target organ 
and disease severity.
In an attempt to explain this variation, Jiang 
and colleagues back-crossed Aire-deficient mice 
onto well-characterized mouse strains and 
showed that genetic background decides their 
fate. Autoimmune-prone nonobese diabetic 
(NOD) mice coped poorly without Aire, suffering 
severe attacks on multiple organs including the 
pancreas, stomach, and lung. C57BL/6 mice fared 
better with a mild disease that was focused 
primarily on the prostate.
Congenic and intercross analyses of the 
NOD.
 
Aire
 
 
 
/
 
 
 
 and C57BL/6/
 
Aire
 
 
 
/
 
 
 
 mice showed 
that pancreatitis was controlled by the same MHC 
haplotype (H-2
 
g7
 
) that predisposes NOD mice to 
diabetes, whereas gastritis was controlled by 
unknown genes on chromosome 3. Further studies 
are required to determine how these modifier 
genes influence the disease manifestations caused 
by the absence of Aire. 
Aire deficiency causes lethal autoimmune disease in 
NOD mice, but only mild disease in C57BL/6 (B6) mice. 
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Vessel-building mast cells
 
Irradiation instructs mast cells to rebuild blood vessels in oxygen-deprived tissues,
according to Heissig and colleagues on page 739. Low-dose irradiation mobilized adult
and precursor mast cells, which traveled to the ischemic tissue and produced the vessel-
building growth factor VEGF (vascular endothelial growth factor).
Ionizing irradiation has been shown to promote the growth of new blood vessels
through the induction of VEGF and inhibition of endothelial cell death. However, the
primary source of irradiation-induced VEGF and the precise mechanism that triggers its
production were not clear. Mast cells—well-known for their production of histamine
in allergic responses—had been found in tissues undergoing angiogenesis. Mast cells are
also capable of producing VEGF, but whether these cells play a leading or supporting
role in angiogenesis had not been explored.
Heissig et al. now show that mast cells are essential for irradiation-induced vessel
growth in a mouse model of ischemic limb injury. Irradiation-induced cellular dam-
age triggers the production of the degradative enzyme matrix metalloprotease-9
(MMP-9) by largely unknown mechanisms. In this model, local irradiation of the
damaged limb increased MMP-9 production in the ischemic tissue, which liberated
the cytokine Kit ligand (KitL), likely from stromal cells. KitL then attracted VEGF-
producing mast cells into the injured tissue.
At the same time, irradiation mobilized mast cell precursors and endothelial cell
progenitors from the bone marrow, and some of these cells became incorporated
into the growing vessels. Without mast cells, the vessel-building benefits of irradiation
were lost. The authors thus speculate that localized irradiation might improve upon
Low-dose irradiation enhances limb re-
generation (bottom) unless mast cells 
are absent (top).
 
current therapies for organ regeneration, which rely on the injection of large numbers of bone
marrow–derived stem cells directly into damaged organs. 
 
CD23 bridges the gap
 
The structure of the low-affinity human immunoglobulin E (IgE) receptor CD23, revealed 
on page 751, accounts for its provocative behavior. Hibbert and colleagues show 
that soluble CD23 (sCD23) can simultaneously bind IgE and the complement 
receptor CD21 on B cells. This binding dexterity helps explain how CD23 and IgE 
cooperate to ramp up the synthesis of more IgE.
The production of IgE—the signature antibody of allergic diseases—is enhanced 
when sCD23 (which is cleaved from the surface of activated B cells by endogenous or 
pathogen-derived proteases) binds to CD21 on other B cells. But it was not clear why 
sCD23 binding to CD21 enhanced the production of IgE but not other antibody 
isotypes, as CD21 is present on all B cells.
The group used NMR spectroscopy to show that sCD23 can bind to both IgE and 
CD21 simultaneously, as their binding sites are nonoverlapping. This dual binding 
capacity allows sCD23 to link IgE and CD21 on the surface of B cells. How this linkage 
triggers IgE production is not yet known, but the process is likely to be similar to one 
initiated by the complement component C3d. C3d, when covalently linked to antigen, 
brings together the B cell receptor (immunoglobulin M) and CD21. This assemblage 
recruits the CD21-associated signaling molecule CD19, which synergizes with the B cell 
receptor to increase activation and proliferation of the cell.
Once IgE levels are high, a trimeric membrane–bound form of CD23 helps turn off IgE 
production, possibly by stabilizing the molecule and preventing its cleavage. The next 
challenge, according to senior author James McDonnell, will be to study CD23-mediated 
IgE regulation in animal models of allergic disease. In the meantime, these data might 
provide a structural basis for the development of novel inhibitors of allergic disease. 
Structure of the CD23 molecule showing the 
binding sites for IgE (green) and CD21 (blue).
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